{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:09:05Z","timestamp":1790370545356,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.neuropharm.2024.110182","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T17:19:07Z","timestamp":1728667147000},"page":"110182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Clinically-probed mechanisms of action in Fragile-X syndrome fail to normalize translational EEG phenotypes in Fmr1 knockout mice"],"prefix":"10.1016","volume":"262","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6472-2956","authenticated-orcid":false,"given":"Philipp","family":"Janz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5832-193X","authenticated-orcid":false,"given":"Marie","family":"Bainier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7641-7206","authenticated-orcid":false,"given":"Samuel","family":"Marashli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3477-689X","authenticated-orcid":false,"given":"Roger L.","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2024.110182_bib1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.tins.2004.04.009","article-title":"The mGluR theory of fragile X mental retardation","volume":"27","author":"Bear","year":"2004","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110182_bib2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrd.2017.221","article-title":"Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome","volume":"17","author":"Berry-Kravis","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2024.110182_bib3","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.4161\/15384101.2014.989114","article-title":"The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome","volume":"14","author":"Braat","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.neuropharm.2024.110182_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.757825","article-title":"Gaboxadol in fragile X syndrome: a 12-week randomized, double-blind, parallel-group, Phase 2a study","volume":"12","author":"Budimirovic","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110182_bib5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fncel.2014.00245","article-title":"The contribution of inhibitory interneurons to circuit dysfunction in Fragile X Syndrome","volume":"8","author":"Cea-Del Rio","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110182_bib6","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0306-4522(01)00036-7","article-title":"Fragile X mice develop sensory hyperreactivity to auditory stimuli","volume":"103","author":"Chen","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2024.110182_bib7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3389\/fnbeh.2019.00141","article-title":"Gaboxadol normalizes behavioral abnormalities in a mouse model of fragile X syndrome","volume":"13","author":"Cogram","year":"2019","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110182_bib8","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/cercor\/bhn159","article-title":"Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome","volume":"19","author":"Curia","year":"2009","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neuropharm.2024.110182_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneumeth.2024.110155","article-title":"Workflow for the unsupervised clustering of sleep stages identifies light and deep sleep in electrophysiological recordings in mice","volume":"408","author":"Cusinato","year":"2024","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2024.110182_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41583-021-00445-9","article-title":"Channelopathies in fragile X syndrome","volume":"22","author":"Deng","year":"2021","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110182_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110820","article-title":"FMRP regulates GABAA receptor channel activity to control signal integration in hippocampal granule cells","volume":"39","author":"Deng","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2024.110182_bib12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.nbd.2008.04.002","article-title":"Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice","volume":"31","author":"de Vrij","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2024.110182_bib13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.brainres.2006.08.115","article-title":"Decreased expression of the GABAA receptor in fragile X syndrome","volume":"1121","author":"D'Hulst","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2024.110182_bib14","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.neuron.2007.12.001","article-title":"Correction of fragile X syndrome in mice","volume":"56","author":"D\u00f6len","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2024.110182_bib15","first-page":"60","article-title":"Auditory EEG biomarkers in fragile X syndrome: clinical relevance. Front. Integr","volume":"13","author":"Ethridge","year":"2019","journal-title":"Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110182_bib16","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/ejhg.2008.61","article-title":"Fragile X syndrome","volume":"16","author":"Garber","year":"2008","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.neuropharm.2024.110182_bib17","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.biopsych.2015.03.010","article-title":"Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia","volume":"77","author":"Gonzalez-Burgos","year":"2015","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110182_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004218","article-title":"Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen","volume":"4","author":"Henderson","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuropharm.2024.110182_bib19","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/GIM.0b013e3181e38fb6","article-title":"A systematic review of population screening for fragile X syndrome","volume":"12","author":"Hill","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.neuropharm.2024.110182_bib20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/jnc.15602","article-title":"GABAB R activation partially normalizes acute NMDAR hypofunction oscillatory abnormalities but fails to rescue sensory processing deficits","volume":"161","author":"Janz","year":"2022","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2024.110182_bib21","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/s41386-020-0697-9","article-title":"A roadmap for development of neuro-oscillations as translational biomarkers for treatment development in neuropsychopharmacology","volume":"45","author":"Javitt","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.110182_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104794","article-title":"Multielectrode array analysis of EEG biomarkers in a mouse model of Fragile X Syndrome","volume":"138","author":"Jonak","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2024.110182_bib66","doi-asserted-by":"crossref","first-page":"6621","DOI":"10.1074\/jbc.M116.772541","article-title":"Deficits in the activity of presynaptic \u03b3-aminobutyric acid type B receptors contribute to altered neuronal excitability in fragile X syndrome","volume":"292","author":"Kang","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2024.110182_bib65","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41593-021-00913-6","article-title":"A human forebrain organoid model of fragile X syndrome exhibits altered neurogenesis and highlights new treatment strategies","volume":"24","author":"Kang","year":"2021","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110182_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41398-022-01796-2","article-title":"EEG as a translational biomarker and outcome measure in fragile X syndrome","volume":"12","author":"Kenny","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2024.110182_bib25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3389\/fnhum.2012.00264","article-title":"Event-related potential alterations in fragile X syndrome","volume":"6","author":"Knoth","year":"2012","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110182_bib26","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijdevneu.2014.05.003","article-title":"Alterations of visual and auditory evoked potentials in fragile X syndrome","volume":"36","author":"Knoth","year":"2014","journal-title":"Int. J. Dev. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110182_bib27","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1073\/pnas.1013855108","article-title":"Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome","volume":"108","author":"Krueger","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2024.110182_bib28","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3109\/00016489109138418","article-title":"Age-related loss of auditory sensitivity in two mouse genotypes","volume":"111","author":"Li","year":"1991","journal-title":"Acta Otolaryngol."},{"key":"10.1016\/j.neuropharm.2024.110182_bib29","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1124\/jpet.111.185660","article-title":"CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor","volume":"339","author":"Lindemann","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2024.110182_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.nbd.2018.03.012","article-title":"Translation-relevant EEG phenotypes in a mouse model of Fragile X Syndrome","volume":"115","author":"Lovelace","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2024.110182_bib31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrn3155","article-title":"Interneuron dysfunction in psychiatric disorders","volume":"13","author":"Mar\u00edn","year":"2012","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110182_bib64","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0300-19.2019","article-title":"Characterization of auditory and binaural spatial hearing in a fragile X syndrome mouse model","volume":"7","author":"McCullagh","year":"2020","journal-title":"eNeuro"},{"key":"10.1016\/j.neuropharm.2024.110182_bib32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.biopsych.2013.05.038","article-title":"Chronic metabotropic glutamate receptor 5 inhibition corrects local alterations of brain activity and improves cognitive performance in fragile X mice","volume":"75","author":"Michalon","year":"2014","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110182_bib33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuron.2012.03.009","article-title":"Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice","volume":"74","author":"Michalon","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2024.110182_bib34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nrneurol.2017.15","article-title":"Translational use of event-related potentials to assess circuit integrity in ASD","volume":"13","author":"Modi","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2024.110182_bib35","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.clinph.2004.04.029","article-title":"Identifying true brain interaction from EEG data using the imaginary part of coherency","volume":"115","author":"Nolte","year":"2004","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2024.110182_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cells10102610","article-title":"Interneuron dysfunction and inhibitory deficits in autism and fragile X syndrome","volume":"10","author":"Nomura","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.neuropharm.2024.110182_bib37","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1159\/000332884","article-title":"The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome","volume":"33","author":"Olmos-Serrano","year":"2011","journal-title":"Dev. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110182_bib38","doi-asserted-by":"crossref","first-page":"9929","DOI":"10.1523\/JNEUROSCI.1714-10.2010","article-title":"Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome","volume":"30","author":"Olmos-Serrano","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110182_bib39","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1124\/jpet.111.183327","article-title":"Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome","volume":"338","author":"Pacey","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2024.110182_bib40","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nrn.2016.141","article-title":"Network abnormalities and interneuron dysfunction in Alzheimer disease","volume":"17","author":"Palop","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110182_bib41","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s42003-022-03395-9","article-title":"Neocortical localization and thalamocortical modulation of neuronal hyperexcitability contribute to Fragile X Syndrome","volume":"5","author":"Pedapati","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.neuropharm.2024.110182_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017073","article-title":"Genetic-background modulation of core and variable autistic-like symptoms in Fmr1 knock-out mice","volume":"6","author":"Pietropaolo","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2024.110182_bib43","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv034","article-title":"R-baclofen reverses a social behavior deficit and elevated protein synthesis in a mouse model of fragile X syndrome","volume":"18","author":"Qin","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2024.110182_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.720752","article-title":"Neural correlates of auditory hypersensitivity in fragile X syndrome","volume":"12","author":"Razak","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110182_bib45","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41583-021-00432-0","article-title":"The molecular biology of FMRP: new insights into fragile X syndrome","volume":"22","author":"Richter","year":"2021","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110182_bib46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00004703-200112000-00008","article-title":"The behavioral phenotype in fragile X: symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders","volume":"22","author":"Rogers","year":"2001","journal-title":"J. Dev. Behav. Pediatr."},{"key":"10.1016\/j.neuropharm.2024.110182_bib47","author":"Saoud"},{"key":"10.1016\/j.neuropharm.2024.110182_bib48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13229-022-00527-0","article-title":"Altered frontal connectivity as a mechanism for executive function deficits in fragile X syndrome","volume":"13","author":"Schmitt","year":"2022","journal-title":"Mol. Autism."},{"key":"10.1016\/j.neuropharm.2024.110182_bib49","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0380-16.2017","article-title":"GABA-B agonist baclofen normalizes auditory-evoked neural oscillations and behavioral deficits in the Fmr1 knockout mouse model of fragile X syndrome","volume":"4","author":"Sinclair","year":"2017","journal-title":"eNeuro"},{"key":"10.1016\/j.neuropharm.2024.110182_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.718953","article-title":"mGluR5 negative modulators for fragile X: treatment resistance and persistence","volume":"12","author":"Stoppel","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110182_bib51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00213-010-2130-2","article-title":"Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome","volume":"215","author":"Su","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.110182_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1171895","article-title":"Fragile X Syndrome as an interneuronopathy: a lesson for future studies and treatments","volume":"17","author":"Tempio","year":"2023","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110182_bib53","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/23808993.2021.2008168","article-title":"Therapeutic potential of GABAA receptor subunit expression abnormalities in fragile X syndrome","volume":"7","author":"van der Lei","year":"2022","journal-title":"Expert Rev. Precis. Med. Drug Dev."},{"key":"10.1016\/j.neuropharm.2024.110182_bib54","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.clinph.2011.08.023","article-title":"Auditory and visual cortical activity during selective attention in fragile X syndrome: a cascade of processing deficiencies","volume":"123","author":"Van der Molen","year":"2012","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2024.110182_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.722378","article-title":"Heterogeneity in fragile X syndrome highlights the need for precision medicine-based treatments","volume":"12","author":"Verdura","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2024.110182_bib56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s11689-017-9191-z","article-title":"A resting EEG study of neocortical hyperexcitability and altered functional connectivity in fragile X syndrome","volume":"9","author":"Wang","year":"2017","journal-title":"J. Neurodev. Disord."},{"key":"10.1016\/j.neuropharm.2024.110182_bib57","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.neuroscience.2018.11.047","article-title":"Developmental changes in EEG phenotypes in a mouse model of fragile X syndrome","volume":"398","author":"Wen","year":"2019","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2024.110182_bib58","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13229-021-00425-x","article-title":"Increased aperiodic gamma power in young boys with Fragile X Syndrome is associated with better language ability","volume":"12","author":"Wilkinson","year":"2021","journal-title":"Mol. Autism."},{"key":"10.1016\/j.neuropharm.2024.110182_bib59","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1399-0004.2011.01723.x","article-title":"CGG repeat in the FMR1 gene: size matters","volume":"80","author":"Willemsen","year":"2011","journal-title":"Clin. Genet."},{"key":"10.1016\/j.neuropharm.2024.110182_bib60","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.169650","article-title":"CNS-dominant human FMRP isoform rescues seizures, fear, and sleep abnormalities in Fmr1-KO mice","volume":"8","author":"Wong","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.neuropharm.2024.110182_bib61","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.neuropharm.2005.06.004","article-title":"Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP","volume":"49","author":"Yan","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.110182_bib62","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.expneurol.2017.08.008","article-title":"Decreased surface expression of the \u03b4 subunit of the GABAA receptor contributes to reduced tonic inhibition in dentate granule cells in a mouse model of fragile X syndrome","volume":"297","author":"Zhang","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2024.110182_bib63","article-title":"GABAB receptor upregulates fragile X mental retardation protein expression in neurons","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci. Rep."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824003514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824003514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T22:13:39Z","timestamp":1738448019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390824003514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":65,"alternative-id":["S0028390824003514"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110182","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinically-probed mechanisms of action in Fragile-X syndrome fail to normalize translational EEG phenotypes in Fmr1 knockout mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110182","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110182"}}